Document:

Supplemental Indenture

 Exhibit 4.14 

SUPPLEMENTAL INDENTURE 

SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of October 4, 2010 among Graham Packaging GP Acquisition
LLC, a Delaware limited liability company (“GPALLC”), Graham Packaging LP Acquisition LLC, a Delaware limited liability company (“LPALLC”), WCK-L Holdings, Inc., a Delaware corporation (“WCK”), Liquid Container Inc., a
Delaware corporation (“LCI”), CPG-L Holdings, Inc., a Delaware corporation (“CPG”), Graham Packaging LC, L.P., a Delaware limited partnership (“Graham Packaging LC”), Graham Packaging PX Holding Corporation, a Delaware
corporation (“Graham PX Holding”), Graham Packaging PX, LLC, a California limited liability company (“Graham PX”), Graham Packaging PX Company, a California general partnership (together with GPALLC, LPALLC, WCK, LCI, CPG, Graham
Packaging LC, Graham PX Holding and Graham PX, the “New Guarantors”), Graham Packaging Company, L.P., a Delaware limited partnership (the “Company”), GPC Capital Corp. I, a Delaware corporation (the “Corporate
Co-Issuer” and, together with the Company, the “Issuers”), the Guarantors listed on the signature pages hereto and THE BANK OF NEW YORK MELLON, a New York banking corporation, as trustee under the indenture referred to below (the
“Trustee”). 
 RECITALS 

WHEREAS the Issuers, the Guarantors and the Trustee have heretofore executed an Indenture (as amended, supplemented
or otherwise modified, the “Indenture”) dated as of November 24, 2009, providing for the issuance of the Issuers’
8 1/4% Senior Notes due 2017 (the
“Notes”), initially in the aggregate principal amount of $253,378,000; 
 WHEREAS Section 10.07 of the
Indenture provides that under certain circumstances the Issuers are required to cause the New Guarantors to execute and deliver to the Trustee a supplemental indenture pursuant to which the New Guarantors shall unconditionally guarantee all the
Issuers’ obligations under the Notes pursuant to a Senior Guarantee on the terms and conditions set forth herein; and 

WHEREAS pursuant to Section 9.01 of the Indenture, the Trustee, the Issuers and the existing Guarantors are authorized to execute
and deliver this Supplemental Indenture; 
 NOW THEREFORE, in consideration of the foregoing and mutual covenants herein
contained and intending to be legally bound, the New Guarantor, the Issuers and the Trustee mutually covenant and agree for the equal and ratable benefit of the holders of the Notes as follows: 

1. Defined Terms. As used in this Supplemental Indenture, terms defined in the Indenture or in the preamble or recital hereto are
used herein as therein defined, except that the term “Holders” in this Guarantee shall refer to the term “Holders” as defined in the Indenture and the Trustee acting on behalf of and for the benefit of such Holders. The words
“herein,” “hereof” and hereby and other words of similar import used in this Supplemental Indenture refer to this Supplemental Indenture as a whole and not to any particular section hereof. 

2. Agreement to Guarantee. The New Guarantors hereby agrees, jointly and severally with all existing Guarantors, to
unconditionally guarantee the Issuers’ obligations under 

 
the Notes on the terms and subject to the conditions set forth in Article 10 of the Indenture and to be bound by all other applicable provisions of the Indenture and the Notes and to perform all
of the obligations and agreements of a Guarantor under the Indenture. 
 3. Notices. All notices or other communications
to the New Guarantors shall be given as provided in Section 11.02 of the Indenture. 
 4. Ratification of Indenture;
Supplemental Indentures Part of Indenture. Except as expressly amended hereby, the Indenture is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect. This Supplemental
Indenture shall form a part of the Indenture for all purposes, and every holder of Notes heretofore or hereafter authenticated and delivered shall be bound hereby. 

5. Governing Law. THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW
YORK. 
 6. Trustee Makes No Representation. The Trustee makes no representation as to the validity or sufficiency of
this Supplemental Indenture. 
 7. Counterparts. The parties may sign any number of copies of this Supplemental
Indenture. Each signed copy shall be an original, but all of them together represent the same agreement. 
 8. Effect of
Headings. The Section headings herein are for convenience only and shall not affect the construction thereof. 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly
executed as of the date first above written. 
  

					
	New Guarantors:
	
	GRAHAM PACKAGING GP ACQUISITION LLC
		
	By:	 	 /s/ David W. Bullock

		 	Name: David W. Bullock
		 	Title: Chief Financial Officer and Vice Chairman
	
	GRAHAM PACKAGING LP ACQUISITION LLC
		
	By:	 	 /s/ David W. Bullock

		 	Name: David W. Bullock
		 	Title: Chief Financial Officer and Vice Chairman
	
	WCK-L HOLDINGS, INC.
		
	By:	 	 /s/ David W. Bullock

		 	Name: David W. Bullock
		 	Title: Chief Financial Officer and Vice Chairman
	
	LIQUID CONTAINER INC.
		
	By:	 	 /s/ David W. Bullock

		 	Name: David W. Bullock
		 	Title: Chief Financial Officer and Vice Chairman

[Signature Page to Senior Supplemental Indenture] 

							
	CPG-L HOLDINGS, INC.
			
	By:	 		 	 /s/ David W. Bullock

		 		 	Name: David W. Bullock
		 		 	Title: Chief Financial Officer and Vice Chairman
	
	GRAHAM PACKAGING LC, L.P.
		
		 	By: Liquid Container Inc., its General Partner
			
	By:	 		 	 /s/ David W. Bullock

		 		 	Name: David W. Bullock
		 		 	Title: Chief Financial Officer and Vice Chairman
	
	GRAHAM PACKAGING PX HOLDING CORPORATION
			
	By:	 		 	 /s/ David W. Bullock

		 		 	Name: David W. Bullock
		 		 	Title: Chief Financial Officer and Vice Chairman
	
	GRAHAM PACKAGING PX, LLC
		
		 	By: Graham Packaging PX Holding Corporation, its Sole Member
			
	By:	 		 	 /s/ David W. Bullock

		 		 	Name: David W. Bullock
		 		 	Title: Chief Financial Officer and Vice Chairman

  

 [Signature Page to Senior Supplemental Indenture] 

					
	GRAHAM PACKAGING PX COMPANY
		
	By:	 	 Graham Packaging PX Holding Corporation,
its partner

	By:	 	 Graham Packaging PX, LLC,
its partner

		
	By:	 	 /s/ David W. Bullock

		 	Name: David W. Bullock
		 	Title: Chief Financial Officer
		
	By:	 	 /s/ David W. Bullock

		 	Name: David W. Bullock
		 	Title: Chief Financial Officer
	
	Issuers:
	
	GPC CAPITAL CORP. I
		
	By:	 	 /s/ David W. Bullock

		 	Name: David W. Bullock
		 	Title: Chief Financial Officer
	
	GRAHAM PACKAGING COMPANY, L.P.
	By:	 	 GPC Opco GP, LLC,
its general partner

		
	By:	 	 /s/ David W. Bullock

		 	Name: David W. Bullock
		 	Title: Chief Financial Officer

  

 [Signature Page to Senior Supplemental Indenture] 

			
	Guarantors:
	
	 GRAHAM PACKAGING HOLDINGS COMPANY

	 By:
	 	 BCP/Graham Holdings LLC,
its general partner

		
	By:	 	 /s/ David W. Bullock

		 	Name: David W. Bullock
		 	Title: Assistant Treasurer
	
	 GPC SUB GP LLC

		
	 By:
	 	 /s/ David W. Bullock

		 	Name: David W. Bullock
		 	Title: Chief Financial Officer and Secretary
	
	 GRAHAM PACKAGING LATIN AMERICA, LLC

		
	 By:
	 	 /s/ David W. Bullock

		 	Name: David W. Bullock
		 	Title: Chief Financial Officer
	
	 GRAHAM PACKAGING POLAND, L.P.

	 By:
	 	 GPACSUB LLC,
its general partner

		
	 By:
	 	 /s/ David W. Bullock

		 	Name: David W. Bullock
		 	Title: Chief Financial Officer and Secretary

  

 [Signature Page to Senior Supplemental Indenture] 

			
	 GRAHAM RECYCLING COMPANY, L.P.

	 By:
	 	 GPC Sub GP LLC,
its general partner

		
	 By:
	 	 /s/ David W. Bullock

		 	Name: David W. Bullock
		 	Title: Chief Financial Officer and Secretary
	
	 GRAHAM PACKAGING FRANCE PARTNERS

	 By:
	 	 Graham Packaging Company, L.P.,
its partner

	 By:
	 	 GPC Opco GP LLC,
its general partner

		
	 By:
	 	 /s/ David W. Bullock

		 	 Name: David W. Bullock

		 	 Title: Chief Financial Officer

	
	 GRAHAM PACKAGING WEST JORDAN, LLC

		
	 By:
	 	 /s/ David W. Bullock

		 	 Name: David W. Bullock

		 	 Title: Chief Financial Officer and Secretary

	
	 GRAHAM PACKAGING ACQUISITION CORP

		
	 By:
	 	 /s/ David W. Bullock

		 	 Name: David W. Bullock

		 	 Title: Chief Financial Officer

	
	 GRAHAM PACKAGING PLASTIC PRODUCTS INC.

		
	 By:
	 	 /s/ David W. Bullock

		 	 Name: David W. Bullock

		 	 Title: Chief Financial Officer

 

 [Signature Page to Senior Supplemental Indenture] 

			
	 GRAHAM PACKAGING PET TECHNOLOGIES INC.

		
	 By:
	 	 /s/ David W. Bullock

		 	 Name: David W. Bullock

		 	 Title: Chief Financial Officer

	
	 GRAHAM PACKAGING REGIOPLAST STS INC.

		
	 By:
	 	 /s/ David W. Bullock

		 	 Name: David W. Bullock

		 	 Title: Chief Financial Officer and Secretary

	
	 GRAHAM PACKAGING INTERNATIONAL PLASTIC PRODUCTS INC.

		
	 By:
	 	 /s/ David W. Bullock

		 	 Name: David W. Bullock

		 	 Title: Chief Financial Officer

	
	 GRAHAM PACKAGING LEASING USA LLC

		
	 By:
	 	 /s/ David W. Bullock

		 	 Name: David W. Bullock

		 	 Title: Chief Financial Officer

 

 [Signature Page to Senior Supplemental Indenture] 

			
	 GRAHAM PACKAGING COMERC USA LLC

		
	By:	 	 /s/ David W. Bullock

		 	Name: David W. Bullock
		 	Title: Chief Financial Officer
	
	 GRAHAM PACKAGING CONTROLLERS USA LLC

		
	By:	 	 /s/ David W. Bullock

		 	Name: David W. Bullock
		 	Title: Chief Financial Officer
	
	 GRAHAM PACKAGING TECHNOLOGICAL SPECIALTIES LLC

		
	By:	 	 /s/ David W. Bullock

		 	Name: David W. Bullock
		 	Title: Chief Financial Officer
	
	 GRAHAM PACKAGING MINSTER LLC

		
	By:	 	 /s/ David W. Bullock

		 	Name: David Bullock
		 	Title: Chief Financial Officer and Secretary
	
	 GPACSUB LLC

		
	By:	 	 /s/ David W. Bullock

		 	Name: David Bullock
		 	Title: Chief Financial Officer and Secretary

  

 [Signature Page to Senior Supplemental Indenture] 

			
	Trustee:
	
	 THE BANK OF NEW YORK MELLON, as Trustee

		
	By:	 	 /s/ Leslie Lockhart

		 	Name: Leslie Lockhart
		 	Title: Senior Associate

  

 [Signature Page to Senior Supplemental Indenture]Securities Purchase Agreement

 Exhibit 10.1 

SECURITIES PURCHASE AGREEMENT 

EnteroMedics Inc. 
 2800 Patton Road 

St. Paul, Minnesota 55113 
 The
undersigned (the “Investor”) hereby confirms its agreement with you as follows: 
 1. This Securities Purchase Agreement
is made as of the date set forth below between EnteroMedics Inc., a Delaware corporation (the “Company”), and the Investor. 

2. The Company, through a Certificate of Designations for Series A Non-Voting Convertible Preferred Stock attached hereto as
Exhibit G (the “Certificate of Designations”) filed with the Delaware Secretary of State immediately prior to the date hereto, has authorized the sale and issuance of (i) up to 3,394,309 shares (the
“Shares”) of the Series A Non-Voting Convertible Preferred Stock of the Company, $.01 par value per share (the “Series A Preferred”), (ii) warrants to purchase up to
3,394,3091 shares of Common Stock (the “Up Front
Warrants”), and (iii) warrants to purchase that number of shares of the Common Stock equal to (A) the difference between the Share Purchase Price and the price per share of Common Stock underlying equity securities paid by
investors in an Equity Offering (as defined in the Certificate of Designations), multiplied by the number of shares of Series A Preferred purchased by the Investor, divided by (B) the warrant exercise price per share, which shall
equal 120% of the Share Purchase Price (the “Conversion Warrants” and, together with the Up Front Warrants, the
“Warrants”))2, to certain investors in a
private placement (the “Offering”). 
 3. The Company and the Investor agree that upon execution of
this Securities Purchase Agreement the Investor will purchase from the Company and the Company will issue and sell to the Investor             Shares at a purchase price of $1.72 per
Share (the “Share Purchase Price”) and Up Front Warrants to purchase             shares of Common Stock (which Warrant shall be exercisable for 100% of the number of
Shares that are purchased under this Agreement by the Investor at an exercise price per share equal to
$2.153 per share at a purchase price of $0.125 per share
of Common Stock underlying the Up Front Warrant (the “Warrant Purchase Price”), all at an aggregate purchase price of
$                             (the “Purchase Price”). Further, upon completion of an
Equity Offering, the Company will issue and sell to the Investor, the Conversion Warrants at a purchase price of $0.125 per share of Common Stock underlying the Conversion Warrants, which shall be payable as provided in Section 7.1(a) of the
Certificate of Designations (the “Conversion Warrant Purchase Price”). All of the forgoing shall be subject to the Terms and Conditions for Purchase of Securities attached hereto as Annex I and incorporated herein by this reference
as if fully set forth herein. Unless otherwise requested by the Investor in Exhibit A, certificates representing the Securities purchased by the Investor will be registered in the Investor’s name and address as set forth below. 

 

	1
	 Equals the number of shares of Preferred Stock Purchased by all Investors. 

	2
	 The Conversion Warrants will only be exercisable if Company completes an Equity Offering (as defined in the Certificate of Designations) and the Share
Purchase Price is more than the Equity Offering Purchase Price (as defined in the Certificate of Designations). 

	3
	 The Up Front Warrant exercise price per share will be 125% of the Share Purchase Price. 

 4. The Investor represents that, except as set forth below, (a) it has had no position, office
or other material relationship within the past three years with the Company or its affiliates, (b) neither it, nor any group of which it is a member or to which it is related, beneficially owns (including the right to acquire or vote) any
securities of the Company and (c) it has no direct or indirect affiliation or association with any Financial Industry Regulatory Authority (“FINRA”) member. Exceptions: 

 
  

(If no exceptions, write “none.” If left blank, response will be deemed to be “none.”) 

 

 2 

 Please confirm that the foregoing correctly sets forth the agreement between us by signing in the space
provided below for that purpose. 
  

			
	Dated as of: September 29, 2010
	
	  

	[Investor Name]

		
	 By:
	 	  

		 	 Name:

		 	 Title:

 

			
	Address:	 	  

	  

	  

 

			
	 AGREED AND ACCEPTED:

	
	 EnteroMedics Inc.

	 By:
	 	  

		 	 Name:

		 	 Title:

  

 3 

 ANNEX I 

TERMS AND CONDITIONS FOR PURCHASE OF
SHARES 
 1. Agreement to Sell and Purchase the Shares and Warrants; Subscription Date. 

1.1 Purchase and Sale. At the Closing (as defined in Section 2), the Company will sell to the Investor, and the Investor will
purchase from the Company, upon the terms and subject to the conditions set forth herein, (i) the number of Shares described in paragraph 3 of the Securities Purchase Agreement attached hereto (collectively with this Annex I and the other
exhibits attached hereto, this “Agreement”) at the Share Purchase Price specified in the Agreement (which price shall be the consolidated closing bid price of the Company’s Common Stock, $.01 par value per share, as reported on
The Nasdaq Capital Market immediately prior to the execution of this Agreement), and (ii) Up Front Warrants, in substantially the form attached hereto as Exhibit E-1, to acquire up to that number of additional shares of Common Stock set
forth in paragraph 3 of the Securities Purchase Agreement attached hereto at the Warrant Purchase Price (the shares of Common Stock issuable upon exercise of or otherwise pursuant to the Warrants issued to the Investors, collectively, the
“Warrant Shares”). Upon completion of an Equity Offering (as defined in the Certificate of Designations), ), the Company will sell to the Investor, and the Investor will purchase from the Company, upon the terms and subject to the
conditions set forth herein, Conversion Warrants, in substantially the form attached hereto as Exhibit E-2, to acquire up to that number of additional shares of Common Stock set forth in paragraph 3 of the Securities Purchase Agreement
attached hereto at the Conversion Warrant Purchase Price. The Shares and Up Front Warrants are sometimes referred to herein collectively as the “Initial Securities” and the Initial Securities, together with the Conversion Warrants,
are sometimes referred to herein collectively as the “Securities.” 
 1.2 Other Investors. As part of
the Offering, the Company proposes to enter into Securities Purchase Agreements in the same form as this Agreement with certain other investors (the “Other Investors”), and the Company expects to complete sales of Shares and
Warrants to them. The Investor and the Other Investors are sometimes collectively referred to herein as the “Investors,” and this Agreement and the Securities Purchase Agreements executed by the Other Investors are sometimes
collectively referred to herein as the “Agreements.” Each Investor must complete a Securities Purchase Agreement, a Securities Certificate Questionnaire (in the form attached as Exhibit A hereto) and an Investor Questionnaire (in
the form attached as Exhibit B hereto) in order to purchase Securities in the Offering. 
 2. Delivery of the
Securities. The completion of the purchase and sale of the Initial Securities (the “Closing”) shall occur on a date specified by the Company (the “Closing Date”) and of which the Investors will be notified
in advance by the Company. At the Closing, the Company shall deliver to the Investor (i) a copy of instructions to Wells Fargo, N.A., the Company’s transfer agent, certified by the corporate secretary of the Company and instructing the
issuance to Investor in book entry form of the number of Shares set forth in paragraph 3 of the Securities Purchase Agreement (or, upon request by Investor, a stock certificate for such number of Shares), such entry (or certificate, as the case may
be) to be registered in the name of the Investor or, if so indicated on the Securities Certificate Questionnaire, in the name of a nominee designated by the Investor, and (ii) an Up Front Warrant, issued in the name of such Investor or, if so
indicated on the Securities Certificate Questionnaire, in the name of a nominee designated by the Investor, pursuant to which such Investor shall have the right to acquire such number of Up Front Warrant Shares set forth in paragraph 3 of the
Securities Purchase Agreement. In exchange for the delivery of the certificates representing such Initial Securities, the Investor shall deliver the Purchase Price to the Company by wire transfer of immediately available funds pursuant to the

  

 1 

 
Company’s written instructions. On the Closing Date, the Company shall cause counsel to the Company to deliver to the Investors a legal opinion, dated the Closing Date, substantially in the
form attached hereto as Exhibit D (the “Legal Opinion”). 
 The Company’s obligation to issue and sell the
Initial Securities to the Investor shall be subject to the following conditions, any one or more of which may be waived by the Company: (a) prior receipt by the Company of an executed copy of this Agreement; (b) completion of purchases and
sales under the Agreements with the Other Investors; (c) the accuracy of the representations and warranties made by the Investor in this Agreement and the fulfillment of the obligations of the Investor to be fulfilled by it under this Agreement
on or prior to the Closing; and (d) the absence of any order, writ, injunction, judgment or decree that questions the validity of the Agreements or the right of the Company to enter into such Agreements or to consummate the transactions
contemplated hereby and thereby. 
 The Investor’s obligation to purchase the Initial Securities shall be subject to the
following conditions, any one or more of which may be waived by the Investor: (a) completion of purchases and sales under the Agreements with the Other Investors for an aggregate purchase price of not less than Five Million Dollars ($5,000,000)
on or before November 1, 2010; (b) the delivery of the Legal Opinion to the Investor by counsel to the Company; (c) the accuracy of the representations and warranties made by the Company in this Agreement on the date hereof and, if
different, on the Closing Date, in which case such representations and warranties that are not subject to materiality qualifications shall be accurate in all material respects and such representations and warranties that are subject to materiality
qualifications shall be true and correct in all respects; (d) the fulfillment of the obligations of the Company to be fulfilled by it under this Agreement on or prior to the Closing; (e) the absence of any order, writ, injunction, judgment
or decree that questions the validity of the Agreements or the right of the Company to enter into such Agreements or to consummate the transactions contemplated hereby and thereby; (f) the filing by the Company of the notice of Listing of
Additional Shares with the Nasdaq Stock Market with respect to the issuance of the Securities, (g) the Company’s Common Stock shall be listed for trading on the Nasdaq Stock Market, and (h) the delivery to the Investor by the
Secretary or Assistant Secretary of the Company of a certificate stating that the conditions specified in this paragraph have been fulfilled. For purposes of this Agreement, “Business Day” shall mean any day other than a Saturday,
Sunday or other day on which the New York Stock Exchange or commercial banks located in Minneapolis, Minnesota are permitted or required by law to close. 

The completion of the purchase and sale of the Conversion Warrants shall occur within five Business Days after the Closing by the Company
of an Equity Offering, of which the Investors will be notified in advance by the Company. At such time the Company shall deliver to the Investor a Conversion Warrant, issued in the name of such Investor or, if so indicated on the Securities
Certificate Questionnaire, in the name of a nominee designated by the Investor, pursuant to which such Investor shall have the right to acquire such number of Conversion Warrant Shares described in paragraph 3 of the Securities Purchase Agreement.
In exchange for the delivery of the certificates representing such Conversion Warrants, the Investor shall deliver the Conversion Warrant Purchase Price to the Company. 
  

 2 

 3. Representations, Warranties and Covenants of the Company. Except (i) as set
forth in the Company disclosure schedules (the “Disclosure Schedules”), which Disclosure Schedules are being delivered to the Investors at the same time as this Agreement, and (ii) as otherwise described in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2009 (and any amendments thereto filed at least two Business Days prior to the date hereof), the Company’s Proxy Statement for its 2010 Annual Meeting of Shareholders, or the
Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2010 and June 30, 2010 (and any amendments thereto filed at least two Business Days prior to the date hereof) or any of the Company’s Current Reports on
Form 8-K filed since November 15, 2007 and at least two Business Days prior to the date hereof (collectively, the “SEC Reports”), the Company hereby represents and warrants to, and covenants with, the Investor as of the date
hereof and the Closing Date, as follows: 
 3.1 Organization. The Company is duly incorporated and validly existing in
good standing under the laws of the State of Delaware. The Company has full power and authority to own, operate and occupy its properties and to conduct its business as presently conducted and is registered or qualified to do business and in good
standing in each jurisdiction in which it owns or leases property or transacts business and where the failure to be so qualified would have a material adverse effect upon the Company or the business, financial condition, properties, operations or
assets of the Company and its subsidiaries as a whole or the Company’s ability to perform its obligations under the Agreements in all material respects (“Material Adverse Effect”). The Company has no “subsidiaries”
(as defined in Rule 405 under the Securities Act of 1933, as amended (the “Securities Act”)), other than EnteroMedics SARL, a Swiss corporation (the “Subsidiary”), all of the capital stock of which is owned by the
Company. For purposes of Section 3 of this Agreement, the term “Company” shall be deemed to refer to both the Company and the Subsidiary, unless the context otherwise requires. The Company has good and marketable title in fee simple
to, or has valid rights to lease or otherwise use, all items of real and personal property that are material to the business of the Company free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that
(i) do not materially interfere with the use of such property by the Company or (ii) would not reasonably be expected to have a Material Adverse Effect. 

3.2 Due Authorization. The Company has all requisite power and authority to execute, deliver and perform its obligations under the
Agreement, the Warrants and the Certificate of Designations (collectively, the “Transaction Documents”). The execution and delivery of the Transaction Documents, and the consummation by the Company of the transactions contemplated
hereby, have been duly authorized by all necessary corporate action and no further action on the part of the Company or its Board of Directors or stockholders is required. The Agreement and Initial Securities have been, and the Conversion Warrants
will upon issuance be, validly executed and delivered by the Company and constitute legal, valid and binding agreements of the Company enforceable against the Company in accordance with their terms, except to the extent (i) rights to indemnity
and contribution may be limited by state or federal securities laws or the public policy underlying such laws, (ii) such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting
creditors’ and contracting parties’ rights generally and (iii) such enforceability may be subject to general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law).

 3.3 Non-Contravention. The execution and delivery of the Transaction Documents, the issuance and sale of the
Securities to be sold by the Company under the Transaction Documents, the fulfillment of the terms of the Transaction Documents and the consummation of the transactions contemplated thereby will not (A) result in conflict with or constitute a
violation of, or default (with the passage of time or otherwise) under, (i) any bond, debenture, note or other evidence of indebtedness, or any material lease, contract, indenture, mortgage, deed of trust, loan agreement, joint venture or other
agreement or instrument to which the Company is a party or by which the Company or the Subsidiaries or their respective properties are bound, except as would not reasonably be expected to have a Material Adverse Effect, (ii) the Certificate of
Incorporation, by-laws or other organizational documents of the Company, as amended, or (iii) any law, administrative regulation, ordinance or order of any court or governmental agency, arbitration panel or authority binding upon the Company or
its properties, except as would not reasonably be expected to have a Material Adverse Effect or (B) result in the creation or imposition of any lien, encumbrance, claim, security interest or restriction whatsoever upon any of the material
properties or assets of the Company or an acceleration of indebtedness pursuant to any obligation, agreement or condition contained in any material bond, debenture, note or any other evidence 

 

 6 

 
of indebtedness or any material indenture, mortgage, deed of trust or any other agreement or instrument to which the Company is a party or by which it is bound or to which any material property
or assets of the Company is subject, except as would not reasonably be expected to have a Material Adverse Effect. No consent, approval, authorization or other order of, or registration, qualification or filing with, any regulatory body,
administrative agency, or other governmental body is required for the execution and delivery of the Transaction Documents by the Company and the valid issuance or sale of the Securities by the Company pursuant to the Transaction Documents, other
than such as have been made or obtained, and except for any filings required to be made under federal or state securities laws. 

3.4 Capitalization. The outstanding capital stock of the Company as of June 30, 2010 is set forth on Schedule 3.4 of the
Disclosure Schedules. The Company has not issued any capital stock since June 30, 2010 other than the exercise of outstanding warrants or stock options. The Securities to be sold pursuant to the Transaction Documents, as well as all shares of
common stock issuable upon conversion of the Series A Preferred, have been duly authorized, and when issued and paid for in accordance with the terms of the Agreements, will be duly and validly issued, fully paid and nonassessable, subject to no
lien, claim or encumbrance (except for any such lien, claim or encumbrance created, directly or indirectly, by the Investor). The Warrant Shares, when issued and paid for in accordance with the terms of the Warrants, will be duly and validly issued,
fully paid and nonassessable, subject to no lien, claim or encumbrance (except for any such lien, claim or encumbrance created, directly or indirectly, by the Investor). The outstanding shares of capital stock of the Company have been duly and
validly issued and are fully paid and nonassessable, have been issued in compliance with the registration requirements of federal and state securities laws, and were not issued in violation of any preemptive rights or similar rights to subscribe for
or purchase securities. Except as set forth on Schedule 3.4 of the Disclosure Schedules and except as disclosed in the SEC Reports, there are no outstanding rights (including, without limitation, preemptive rights), warrants or options to acquire,
or instruments convertible into or exchangeable for, any unissued shares of capital stock or other equity interest in the Company, or any contract, commitment, agreement, understanding or arrangement of any kind to which the Company is a party and
providing for the issuance or sale of any capital stock of the Company, any such convertible or exchangeable securities or any such rights, warrants or options. Without limiting the foregoing, no preemptive right, co-sale right, registration right,
right of first refusal or other similar right exists with respect to the issuance and sale of the Securities, except as provided in the Transaction Documents or except for such rights as may have been waived prior to the date of this Agreement.
There are no shareholders agreements, voting agreements or other similar agreements with respect to the Common Stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s shareholders.

 3.5 Legal Proceedings. There is no material legal, regulatory or governmental proceeding pending, or to the knowledge
of the Company, threatened, to which the Company is a party or of which the business or property of the Company is subject that is required to be disclosed and that is not so disclosed in the SEC Reports. The Company is not subject to any
injunction, judgment, decree or order of any court, regulatory body, administrative agency or other government body. Neither the Company, nor any director or officer thereof, is or has been the subject of any action involving a claim of violation of
or liability under federal or state securities laws or a claim of breach of fiduciary duty relating to the Company. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the SEC or state
securities commission involving the Company or any current or former director or officer of the Company. The Company has not received any stop order or other order suspending the effectiveness of any registration statement filed by the Company under
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or the Securities Act and, to the Company’s knowledge, the SEC has not issued any such order. There are no material disagreements presently existing, or
reasonably anticipated by the Company to arise, between the independent accounting firms formerly or presently engaged by the Company. 
  

 4 

 3.6 No Violations. The Company is not in violation of its Certificate of
Incorporation, bylaws or other organizational documents, as amended, or in violation of any law, administrative regulation, ordinance or order of any court or governmental agency, arbitration panel or authority applicable to the Company, which
violation, individually or in the aggregate, would reasonably be likely to have a Material Adverse Effect, and the Company is not in default (and there exists no condition which, with the passage of time or otherwise, would constitute a default) in
the performance of any bond, debenture, note or any other evidence of indebtedness or any indenture, mortgage, deed of trust or any other material agreement or instrument to which it is a party or by which it or its property is bound, which default
would reasonably be likely to have a Material Adverse Effect. 
 3.7 Compliance and Governmental Permits, Etc. The
Company has all necessary franchises, licenses, certificates and other authorizations from any foreign, federal, state or local government or governmental agency, department or body that are currently necessary for the operation of the business of
the Company as currently conducted, except where the failure to currently possess such franchises, licenses, certificates and other authorizations is not reasonably expected to have a Material Adverse Effect. The Company has not received any actual
notice of any proceeding relating to revocation or modification of any such franchise, permit, license, or similar authority except where such revocation or modification would not reasonably be expected to have a Material Adverse Effect. The Company
is not in violation of any statute, rule or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws applicable to its business except in each case as could not reasonably be expected to have
a Material Adverse Effect. 
 3.8 Intellectual Property. 

(a) Except for matters which are not reasonably likely to have a Material Adverse Effect, (i) the Company has ownership of,
or a license or other legal right to use, all patents, patent rights, copyrights, trade secrets, trademarks, trade names, designs, manufacturing or other processes, or other proprietary rights used in the business of the Company (collectively,
“Intellectual Property”) and (ii) all of the Intellectual Property owned by the Company consisting of patents, registered trademarks and registered copyrights have been duly registered in, filed in or issued by the United
States Patent and Trademark Office, the United States Register of Copyrights or the corresponding offices of other jurisdictions (including foreign jurisdictions) and have been maintained and renewed in accordance with all applicable provisions of
law and administrative regulations in the United States and/or such other jurisdictions. 
 (b) Except for matters which
are not reasonably likely to have a Material Adverse Effect, all material licenses or other material agreements under which (i) the Company employs rights in Intellectual Property, or (ii) the Company has granted rights to others in
Intellectual Property owned or licensed by the Company are in full force and effect, and there is no default by the Company or, to the knowledge of the Company, any third party with respect thereto. 

(c) Except for matters which are not reasonably likely to have a Material Adverse Effect, to the knowledge of the Company,
(i) the present business, activities and products of the Company do not infringe any intellectual property of any other person; and (ii) the Company is not making unauthorized use of any confidential information or trade secrets of any
person. 
 (d) No proceedings are pending, or to the knowledge of the Company, threatened, which challenge the rights of
the Company to the use of Intellectual Property, except for matters which are not reasonably likely to have a Material Adverse Effect. The Company has not received any written notice that any of the Intellectual Property used by the Company violates
or infringes upon the rights of any other person. 
  

 5 

 3.9 Financial Statements. The consolidated financial statements of the Company and
the related notes contained in the SEC Reports present fairly and accurately in all material respects the financial position of the Company as of the dates indicated, and the results of its operations, cash flows and the changes in
stockholders’ equity for the periods therein specified, subject, in the case of unaudited financial statements for interim periods, to normal year-end audit adjustments. Such consolidated financial statements (including the related notes) have
been prepared in accordance with generally accepted accounting principles applied on a consistent basis at the times and throughout the periods therein specified, except that unaudited financial statements may not contain all footnotes required by
generally accepted accounting principles of the United States (“GAAP”). 
 3.10 No Material Adverse
Change. Except as disclosed in the SEC Reports or in any press releases issued by the Company at least two (2) Business Days prior to the date of this Agreement, since June 30, 2010, there has not been (i) an event, circumstance
or change that has had or is reasonably likely to have a Material Adverse Effect, (ii) any obligation incurred by the Company, direct or contingent, that is material to the Company, (iii) any dividend or distribution of any kind declared,
paid or made on the capital stock of the Company, (iv) any loss or damage (whether or not insured) to the physical property of the Company which has had a Material Adverse Effect, (v) any material change in the Company’s method of
accounting, or (vi) any issuance of equity securities to any officer, director or affiliate, except pursuant to existing Company stock option plans or agreements. 

3.11 Nasdaq Compliance. The Company’s Common Stock is registered pursuant to Section 12(b) of the Exchange Act, and is
listed on The Nasdaq Capital Market (the “Nasdaq Stock Market”), and the Company has taken no action intended to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the
Exchange Act or delisting the Common Stock from the Nasdaq Stock Market, nor has the Company received any notification that the SEC or the Nasdaq Stock Market is contemplating terminating such registration or listing, except as disclosed in the SEC
Reports and on Schedule 3.11 of the Disclosure Schedules. The issuance of the Securities does not require shareholder approval, including, without limitation, pursuant to the Nasdaq Marketplace Rule 5635(d). 

3.12 Reporting Status. The Company has timely made all filings required under the Exchange Act during the 12 months preceding the
date of this Agreement, and all of those documents complied in all material respects with the SEC’s requirements as of their respective filing dates, and the information contained therein as of the respective dates thereof did not contain an
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein in light of the circumstances under which they were made not misleading. The Company is currently eligible
and will remain eligible to register the resale of the Registrable Securities by the Investors pursuant to a registration statement on Form S-3 under the Securities Act as provided in Section 6.1 hereof (the “Registration
Statement”). 
 3.13 No Manipulation; Disclosure of Information. The Company has not taken and will not take any
action designed to or that might reasonably be expected to cause or result in an unlawful manipulation of the price of the Common Stock to facilitate the sale or resale of the Securities. The Company has not disclosed any material non-public
information to the Investors. 
 3.14 Accountants. Deloitte & Touche LLP, who expressed their opinion with
respect to the consolidated financial statements to be incorporated by reference from the Company’s Annual Report on Form 10-K for the year ended December 31, 2009 into the Registration Statement and the prospectus which forms a part
thereof (the “Prospectus”), have advised the Company that they are, and to the knowledge of the Company they are, independent accountants as required by the Securities Act and the rules and regulations promulgated thereunder (the
“Rules and Regulations”). 
  

 6 

 3.15 Contracts. Except for matters which are not reasonably likely to have a Material
Adverse Effect and those contracts that are substantially or fully performed or expired by their terms, the contracts listed as exhibits to or described in the SEC Reports that are material to the Company and all amendments thereto, are in full
force and effect on the date hereof, and neither the Company nor, to the Company’s knowledge, any other party to such contracts is in breach of or default under any of such contracts. The Company has not received a notice of termination nor is
the Company otherwise aware of any written threats to terminate any such contracts. All material agreements that were required to be filed as exhibits to the SEC Reports under Item 601 of Regulation S-K to which the Company or the Subsidiary is
a party, or the property or assets of the Company or the Subsidiary are subject, have been filed as exhibits to the SEC Reports. 

3.16 Taxes. Except for matters which are not reasonably expected to have a Material Adverse Effect, each of the Company and the
Subsidiaries has filed all necessary federal, state and foreign income and franchise tax returns and has paid or accrued all taxes shown as due thereon, and the Company has no knowledge of a tax deficiency which has been asserted or threatened
against the Company. 
 3.17 Transfer Taxes. On the Closing Date, all stock transfer or other taxes (other than income
taxes) which are required to be paid in connection with the sale and transfer of the Shares hereunder will be, or will have been, fully paid or provided for by the Company and the Company will have complied with all laws imposing such taxes.

 3.18 Investment Company. The Company is not an “investment company” or an “affiliated person” of,
or “promoter” or “principal underwriter” for an investment company, within the meaning of the Investment Company Act of 1940, as amended, and will not be deemed an “investment company” as a result of the transactions
contemplated by this Agreement or as a result of the conduct of its business. 
 3.19 Insurance. The Company maintains
insurance of the types and in the amounts that the Company reasonably believes is adequate for its businesses, including, but not limited to, insurance covering real and personal property owned or leased by the Company against theft, damage,
destruction, acts of vandalism and all other risks customarily insured against by similarly situated companies, all of which insurance is in full force and effect. The Company has not received any written notice that the Company will not be able to
renew its existing insurance coverage as and when such coverage expires. The Company believes, based on information that is currently available, that it will be able to obtain similar insurance coverage at reasonable cost from similar insurers as
may be necessary to continue its business as currently conducted. 
 3.20 Offering Prohibitions. Neither the Company nor
any person acting on its behalf or at its direction has in the past or will in the future take any action to sell, offer for sale or solicit offers to buy any securities of the Company which would bring the offer or sale of the Shares as
contemplated by this Agreement within the provisions of Section 5 of the Securities Act. The Company has not made any offers or sales of any security or solicited any offers to buy any security, under any circumstances that would require
registration of the Securities under the Securities Act. Assuming the accuracy of the Investors’ representations and warranties set forth in this Agreement, no registration under the Securities Act is required for the offer and sale of the
Securities by the Company to the Investors as contemplated hereby. The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the Nasdaq Stock Market 

3.21 Listing. The Company has complied and shall comply with all requirements of FINRA and the Nasdaq Stock Market with respect to
the issuance of the Securities, including the 
  

 7 

 
obligation to file the notice of Listing of Additional Shares with the Nasdaq Stock Market. The Company shall use its best efforts to maintain the listing of the Company’s Common Stock on
the Nasdaq Stock Market. 
 3.22 Related Party Transactions. No transaction has occurred between or among the Company or
any of its affiliates, officers or directors or any affiliate or affiliates of any such officer or director that with the passage of time will be required to be disclosed pursuant to Section 13, 14 or 15(d) of the Exchange Act. Except as set
forth on Schedule 3.22 of the Disclosure Schedules, none of the officers or directors of the Company and, to the knowledge of the Company, none of the employees of the Company is presently a party to any transaction with the Company or any
Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or
otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or
partner, in each case in excess of $120,000 other than (i) for payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) for other employee benefits,
including stock option agreements under any stock option plan of the Company. 
 3.23 Registration Rights. Other than
each of Investors, no person or entity has any right to cause the Company to effect the registration under the Securities Act of any securities of the Company, other than registration statements which have already been filed and declared effective
or registration rights which have been waived prior to the date hereof. No person has the right to prohibit the Company from filing a registration statement in accordance with Section 6 hereof. The granting and performance of the registration
rights under this Agreement will not violate or conflict with, or result in a breach of any provision of, or constitute a default under, any agreement, indenture, or instrument to which the Company is a party. The Company covenants that it shall
provide and cause to be maintained a registrar and transfer agent for all Registrable Securities covered by any Registration Statement from and after a date not later than the initial effective date of such Registration Statement. 

3.24 Books and Records. The books, records and accounts of the Company accurately and fairly reflect, in reasonable detail, the
transactions in, and dispositions of, the assets of, and the operations of, the Company. The Company is in material compliance with all provisions of the Sarbanes-Oxley Act of 2002 which are applicable to it as of the Closing Date. The Company
maintains a system of internal controls over financial reporting (as such term is defined in Rule 13a-15(f) of the Exchange Act) sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s
general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in
accordance with management’s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.
The Company has established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and designed such disclosure controls and procedures to ensure that material information relating to the
Company is made known to the certifying officers by others within those entities, particularly during the period in which the Company’s most recently filed periodic report under the Exchange Act, as the case may be, is being prepared. The
Company’s certifying officers have evaluated the effectiveness of the Company’s controls and procedures as of the end of the period prior to the filing date of the most recently filed quarterly or annual periodic report under the Exchange
Act (such date, the “Evaluation Date”). The Company presented in its most recently filed quarterly or annual periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the
disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no 

 

 8 

 
significant changes in the Company’s internal controls over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) or, to the Company’s knowledge, in
other factors, that has materially affected, or is reasonably likely to materially affect, the Company’s internal controls over financial reporting. 

3.25 Foreign Corrupt Practices. Neither the Company, nor any director, officer, agent, employee or other person acting on behalf
of the Company has, in the course of its actions for, or on behalf of, the Company, has (i) directly or indirectly, used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political
activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; (iii) violated or is in violation of in any material respect any provision of the U.S. Foreign
Corrupt Practices Act of 1977, as amended; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government official or employee. 

3.26 Application of Takeover Protections. The execution and delivery of this Agreement and the consummation of the transactions
contemplated hereby will not create in any party (including any current stockholder of the Company) any rights, under any share acquisition, business combination, poison pill (including any distribution under a rights agreement), or other similar
anti-takeover provisions under the Company’s charter documents or the laws of its state of incorporation. 
 3.27
Company Acknowledgement of Purchaser Representation. The Company acknowledges and agrees that Investor does not make or has not made any representations or warranties with respect to the transactions contemplated hereby other than those
specifically set forth in paragraph 4 of the Securities Purchase Agreement, Section 4 of this Agreement, and in the Investor Questionnaire. 

3.28 Acknowledgment Regarding Investors’ Purchase of Securities. The Company acknowledges and agrees that each of the
Investors is acting solely in the capacity of an arm’s length purchaser with respect to this Agreement and the transactions contemplated hereby. The Company further acknowledges that no Investor is acting as a financial advisor or fiduciary of
the Company (or in any similar capacity with respect to the Company) with respect to this Agreement and the transactions contemplated hereby and any advice given by any Purchaser or any of their respective representatives or agents to the Company in
connection with this Agreement and the transactions contemplated hereby is merely incidental to such Investor’s purchase of the Securities. The Company further represents to each Investor that the Company’s decision to enter into this
Agreement has been based on the independent evaluation of the transactions contemplated hereby by the Company and its representatives. 

3.29 Clinical Procedures. The Company, to its knowledge, is conducting (or is causing to be conducted), and has conducted (or
caused to be conducted) all aspects of its research and development activities related to the products that it is developing (the “Products”), including, without limitation, the preclinical and clinical tests and studies of
such Products, in compliance in all material respects with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and applicable local, state and federal laws, rules, regulations and guidances,
including, but not limited to, the principles of Good Clinical Practice, the Federal Food, Drug and Cosmetic Act and implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58 and 312, and has made all reports, filings and notifications required
thereunder, including, but not limited to, the reports required by 21 C.F.R. § 312.32. To the Company’s knowledge, research involving human subjects conducted by or for the Company has (i) been conducted in compliance in all material
respects with all applicable federal, state, and foreign statutes and regulations governing the protection of human subjects and (ii) not involved any investigator who has been disqualified as a clinical investigator by the FDA or any other
agency. To the Company’s knowledge, the Company has conducted its clinical investigations in accordance in all material respects 

 

 9 

 
with Institutional Review Board approvals and requirements, if applicable, and, to its knowledge has obtained informed patient consent where required by the applicable requirements of 21 C.F.R.
Part 50 and any other requirements of the applicable jurisdiction, except where the failure to obtain such consent would not adversely affect the Company. To the Company’s knowledge, the Company is not the subject of any investigation by the
FDA or any other agency. Neither the FDA nor any other regulatory authority has issued any clinical hold orders, warning letters, notices of violation, or similar correspondence or communications with respect to such tests, studies or Products.

 4. Representations, Warranties and Covenants of the Investor. 

4.1 Investor Knowledge and Status. The Investor represents and warrants to the Company on the date hereof and the date of issuance
of the Conversion Warrants, and covenants with, the Company that: (i) the Investor is an “accredited investor” as defined in Regulation D under the Securities Act, is knowledgeable, sophisticated and experienced in making, and is
qualified to make decisions with respect to, investments in securities presenting an investment decision similar to that involved in the purchase of the Securities, and has requested, received, reviewed and considered all information it deemed
relevant in making an informed decision to purchase the Securities; (ii) the Investor understands that the Securities are “restricted securities” and have not been registered under the Securities Act and is acquiring the number of
Securities set forth in paragraph 3 of the Securities Purchase Agreement in the ordinary course of its business and for its own account for investment only, has no present intention of distributing any of such Securities and has no arrangement or
understanding with any other persons regarding the distribution of such Securities (this representation and warranty not limiting the Investor’s right to sell Registrable Securities (as defined in Section 6.1(a)) pursuant to the
Registration Statement or otherwise, or other than with respect to any claim arising out of a breach of this representation and warranty, the Investor’s right to indemnification under Section 6.4); (iii) the Investor will not,
directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise acquire or take a pledge of) any of the Securities except in compliance with the Securities Act, applicable state
securities laws and the respective rules and regulations promulgated thereunder; (iv) the Investor has answered all questions in paragraph 4 of the Securities Purchase Agreement and the Investor Questionnaire attached hereto as Exhibit B for
use in preparation of the Registration Statement and the answers thereto are true and correct as of the date hereof and will be true and correct as of the Closing Date; (v) the Investor will notify the Company promptly of any change in any of
such information until such time as the Investor has sold all of its Securities or until the Company is no longer required to keep the Registration Statement effective; and (vi) the Investor has, in connection with its decision to purchase the
number of Securities set forth in paragraph 3 of the Securities Purchase Agreement, relied only upon the representations and warranties of the Company contained herein and the information contained in the SEC Reports. The Investor understands that
the issuance of the Securities to the Investor has not been registered under the Securities Act, or registered or qualified under any state securities law, in reliance on specific exemptions therefrom, which exemptions may depend upon, among other
things, the representations made by the Investor in this Agreement. No person is authorized to provide any representation that is inconsistent or in addition to those contained herein or in the SEC Reports, and the Investor acknowledges that it has
not received or relied on any such representations. 
 4.2 Transfer of Securities. The Investor agrees that it will not
make any sale, transfer or other disposition of the Securities (a “Disposition”) other than Dispositions of Registrable Securities that are made by Investors pursuant to the Registration Statement or Dispositions by Investors that
are exempt from registration under the Securities Act and, if made pursuant to the Registration Statement by Investors, without complying with any applicable prospectus delivery requirements. 

 

 10 

 4.3 Power and Authority. The Investor represents and warrants to the Company that
(i) the Investor has full right, power, authority and capacity to enter into the Transaction Documents and to consummate the transactions contemplated thereby and has taken all necessary action to authorize the execution, delivery and
performance of the Transaction Documents, and (ii) the Transaction Documents constitute valid and binding obligations of the Investor enforceable against the Investor in accordance with their terms, except as enforceability may be limited by
applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting parties’ rights generally and except as enforceability may be subject to general principles of equity (regardless of whether
such enforceability is considered in a proceeding in equity or at law) and except as the indemnification agreements of the Investors herein may be legally unenforceable. 

4.4 Short Position. The Investor has not established any hedge or other position in the Common Stock that is outstanding on the
Closing Date and is designed to or could reasonably be expected to lead to or result in a Disposition by the Investor or any other person or entity. For purposes hereof, a “hedge or other position” would include, without limitation,
effecting any short sale or having in effect any short position (whether or not such sale or position is against the box and regardless of when such position was entered into) or any purchase, sale or grant of any right (including, without
limitation, any put or call option) with respect to the Common Stock or with respect to any security (other than a broad-based market basket or index) that includes, relates to or derives any significant part of its value from the Common Stock.

 4.5 No Investment, Tax or Legal Advice. The Investor understands that nothing in the SEC Reports, this Agreement, or
any other materials presented to the Investor in connection with the purchase and sale of the Securities constitutes legal, tax or investment advice. The Investor has consulted such legal, tax and investment advisors as it, in its sole discretion,
has deemed necessary or appropriate in connection with its purchase of Securities. 
 4.6 Confidential Information. The
Investor covenants that from the date hereof it will maintain in confidence all material non-public information regarding the Company received by the Investor from the Company, including the receipt and content of any Suspension Notice (as defined
in Section 6.2(c)) until such information (a) becomes generally publicly available other than through a violation of this provision by the Investor or its agents or (b) is required to be disclosed in legal proceedings (such as a
request of a regulatory authority, by deposition, interrogatory, request for documents, subpoena, civil investigation demand, filing with any governmental authority, regulatory body or similar process) or otherwise compelled, upon advise of legal
counsel, to be disclosed to the extent necessary for purposes of enforcing the Investor’s rights under the Transaction Agreements; provided, however, that before making any disclosure in reliance on this Section 4.6, the Investor will give
the Company prior written notice, as soon as reasonably practicable and if not prohibited under law or regulation, specifying the circumstances giving rise thereto and will furnish only that portion of the non-public information which is legally
required and will exercise its commercially reasonable efforts to ensure that confidential treatment will be accorded any non-public information so furnished. The parties acknowledge and agree that as of the date hereof and as of the Closing Date,
the Company has not disclosed any material non-public information to the Investor. 
 4.7 Additional Acknowledgement. The
Investor acknowledges that it has independently evaluated the merits of the transactions contemplated by this Agreement, that it has independently determined to enter into the transactions contemplated hereby, that it is not relying on any advice
from or evaluation by any other Investor, and that it is not acting in concert with any other Investor (other than Investors who may be directly affiliated with such Investor) in making its purchase of the Securities hereunder. The Investor and, to
its knowledge, the Company acknowledge that the Investors have not taken any actions that would deem the Investors to be members of a “group” for purposes of 

 

 11 

 
Section 13(d) of the Exchange Act. Such Investor is not purchasing the Securities as a result of any advertisement, article, notice or other communication regarding the Securities published
in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any other general solicitation or general advertisement. 

5. Survival of Representations, Warranties and Agreements. Notwithstanding any investigation made by any party to this Agreement,
all covenants, agreements, representations and warranties made by the Company and the Investor herein shall survive the execution of this Agreement, the delivery to the Investor of the Securities being purchased and the payment therefor, and a
party’s reliance on such representations and warranties shall not be affected by any investigation made by such party or any information developed thereby. 

6. Registration of Registrable Securities; Compliance with the Securities Act. 

6.1 Registration Procedures and Expenses. The Company shall: 

(a) subject to receipt of necessary information from the Investors (which shall include completion of the questionnaire attached
hereto as Exhibit F, which form shall be completed and returned to the Company not less than five Business Days prior to the filing date of the Registration Statement), prepare and file with the Securities and Exchange Commission
(“SEC”), within forty-five (45) days after the completion of an Equity Offering (the “Required Filing Date”), a Registration Statement on Form S-3 to enable the resale of the Registrable Securities by the
Investors from time to time on a continuous basis pursuant to Rule 415 of the Securities Act. For purposes of this Agreement, “Registrable Securities” means the shares of Common Stock issued upon conversion of the Series A Preferred
pursuant to Section 7(b) of the Certificate of Designations, as well as all Warrant Shares issuable pursuant to the Warrants; provided, however, that the number of Registrable Securities that the Company shall be obligated to register under the
Securities Act shall be limited to that amount which it is permitted to register pursuant to the instructions of Form S-3 or such other amounts as may be permitted by SEC guidance. 

(b) use its best efforts, subject to receipt of necessary information from the Investors, to cause the Registration Statement to
become effective as soon as practicable after the Registration Statement is filed by the Company, but in any event no later than 4:00 p.m. Eastern Time on the 90th day after the Required Filing Date, or if the Registration Statement is reviewed by
the SEC, on the 135th day after the Required Filing Date (such date, as applicable, the “Required Effective Date”).; 

(c) use its best efforts to cause any Prospectus used in connection with any Registration Statement to be filed with the SEC
pursuant to Rule 424(b) under the Securities Act as soon as practicable but in any event no later than 9:00 a.m. Eastern Time the next day that is not a weekend or holiday and the Nasdaq Stock Market is not closed following the date such
Registration Statement is declared effective by the SEC and prepare and file with the SEC such amendments and supplements to the Registration Statement and the Prospectus used in connection therewith as may be necessary to keep the Registration
Statement current and effective for a period ending on the earlier of (i) the first anniversary of the Closing Date (such period of time to be extended by the period of any Suspension (as defined in Section 6.2(c) or any period of time
that the Shares are not listed for or suspended from trading on the Nasdaq Stock Market), (ii) the date on which the Investor may sell Registrable Securities pursuant to Rule 144 without limitations on volume or manner of sales or
(iii) such time as all Registrable Securities purchased by such Investor in this Offering have been sold pursuant to a registration statement or Rule 144, and to notify each Investor promptly upon the Registration Statement and each
post-effective amendment thereto, being declared effective by the SEC; 
  

 12 

 (d) notwithstanding the other provisions of this Agreement, if at any time the SEC
takes the position that some or all of the Registrable Securities may not be included in the Registration Statement because (i) the inclusion of such Registrable Securities violates the provisions of Rule 415 or the instructions of Form S-3 as
a result of the number of shares included in such Registration Statement, and/or (ii) the Registrable Securities cannot be sold as an “at the market offering,” the Company shall (A) remove from the Registration Statement such
portion of the Registrable Securities (the “Cut Back Shares” ) and/or (B) agree to such restrictions and limitations on the registration and resale of the Registrable Securities as the SEC may require to assure the
Company’s compliance with the requirements of Rule 415 (collectively, the “SEC Restrictions” ). Any cut-back imposed pursuant to this Section 6.1(d) shall be allocated among the Investors on a pro rata basis. From and
after such time as the Company is able to effect the registration of the Cut Back Shares in accordance with any SEC Restrictions (such date, the “Restriction Termination Date” ) all of the provisions of this Section 6.1(d)
shall again be applicable to the Cut Back Shares; provided, however, that for such purposes the Filing Date shall be deemed to be the Restriction Termination Date; 

(e) furnish to the Investor with respect to the Registrable Securities registered under the Registration Statement such number of
copies of the Registration Statement, and the Prospectus (including supplemental prospectuses) as the Investor may reasonably request, in order to facilitate the public sale or other disposition of all or any of the Registrable Securities by the
Investor; 
 (f) file documents required of the Company for normal blue sky clearance in states specified in writing by
the Investor; provided, however, that the Company shall not be required to qualify to do business or consent to general service of process in any jurisdiction in which it is not now so qualified or has not so consented; 

(g) bear all expenses (other than underwriting discounts and commissions, if any) in connection with the procedures in paragraph
(a) through (f) of this Section 6.1 and the registration of the Registrable Securities pursuant to the Registration Statement; 

(h) advise the Investors, promptly after it shall receive notice or obtain knowledge of the issuance of any stop order by the SEC
or any other federal or state governmental authority delaying or suspending the effectiveness of the Registration Statement or of the initiation of any proceeding for that purpose; and it will promptly use its commercially reasonable efforts to
prevent the issuance of any stop order or to obtain its withdrawal at the earliest possible moment if such stop order should be issued. 

(i) with a view to making available to the Investor the benefits of Rule 144 and any other rule or regulation of the SEC that may
at any time permit the Investor to sell Shares or Warrant Shares to the public without registration, the Company covenants and agrees to use its commercially reasonable efforts to: (i) make and keep public information available, as those terms
are understood and defined in Rule 144, until the earlier of (A) such date as all of the Investor’s Securities (including common stock issuable upon exercise thereof) may be resold pursuant to Rule 144 without volume or manner of sales
limitations or any other rule of similar effect or (B) such date as all of the Investor’s Shares shall have been resold; (ii) file with the SEC in a timely manner all reports and other documents required of the Company under the
Securities Act and under the Exchange Act; and (iii) furnish to the Investor upon request, as long as the Investor owns any Securities, (A) a written statement by the Company that it has complied with the reporting requirements of the
Securities Act and the Exchange Act, (B) a copy of the Company’s most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q, and (C) such other information as may be reasonably requested in order to avail the Investor of
any rule or regulation of the SEC that permits the selling of any such Securities (including common stock issuable upon exercise thereof) without registration. 
  

 13 

 It shall be a condition precedent to the obligations of the Company to take any action
pursuant to this Section 6.1 that the Investor shall furnish to the Company such information regarding itself, the Registrable Securities to be sold by Investor, and the intended method of disposition of such securities as shall be required to
effect the registration of the Registrable Securities. 
 The Company understands that the Investor disclaims being an
underwriter, but acknowledges that a determination by the SEC that the Investor is deemed an underwriter shall not relieve the Company of any obligations it has hereunder. 

6.2 Transfer of Shares After Registration; Suspension. 

(a) Each Investor agrees that it will not effect any Disposition of the Securities or Warrant Shares or its right to purchase the
Securities or Warrant Shares that would constitute a sale within the meaning of the Securities Act other than transactions exempt from the registration requirements of the Securities Act, except as contemplated in the Registration Statement referred
to in Section 6.1 and as described below, and that it will promptly notify the Company of any material changes in the information set forth in the Registration Statement regarding the Investor or its plan of distribution. 

(b) Except in the event that paragraph (c) below applies, the Company shall: (i) if deemed necessary by the Company,
prepare and file from time to time with the SEC a post-effective amendment to the Registration Statement or a supplement to the related Prospectus or a supplement or amendment to any document incorporated therein by reference or file any other
required document so that such Registration Statement will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, and so that, as
thereafter delivered to purchasers of the Registrable Securities being sold thereunder, such Prospectus will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances under which they were made, not misleading; (ii) provide the Investor copies of any documents filed pursuant to Section 6.2(b)(i); and (iii) upon request, inform each Investor who so
requests that the Company has complied with its obligations in Section 6.2(b)(i) (or that, if the Company has filed a post-effective amendment to the Registration Statement which has not yet been declared effective, the Company will notify the
Investor to that effect, will use its best efforts to secure the effectiveness of such post-effective amendment as promptly as possible and will promptly notify the Investor pursuant to Section 6.2(b)(i) hereof when the amendment has become
effective). 
 (c) Subject to paragraph (d) below, in the event: (i) of any request by the SEC or any other
federal or state governmental authority during the period of effectiveness of the Registration Statement for amendments or supplements to the Registration Statement or related Prospectus or for additional information; (ii) of the issuance by
the SEC or any other federal or state governmental authority of any stop order suspending the effectiveness of the Registration Statement or the initiation of any proceedings for that purpose; (iii) of the receipt by the Company of any
notification with respect to the suspension of the qualification or exemption from qualification of any of the Registrable Securities for sale in any jurisdiction or the initiation of any proceeding for such purpose; or (iv) of any event or
circumstance which necessitates the making of any changes in the Registration Statement or Prospectus, or any document incorporated or deemed to be incorporated therein by reference, so that, in the case of the Registration Statement, it will not
contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading, and that in the case of the Prospectus, it will not contain any untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; then the Company shall promptly
deliver a certificate in writing to the Investor (the 
  

 14 

 
“Suspension Notice”) to the effect of the foregoing and, upon receipt of such Suspension Notice, the Investor will refrain from selling any Shares pursuant to the Registration
Statement (a “Suspension”) until the Investors are advised in writing by the Company that the current Prospectus may be used, and has received copies of any additional or supplemental filings that are incorporated or deemed
incorporated by reference in any such Prospectus. In the event of any Suspension, the Company will use its reasonable best efforts to cause the use of the Prospectus so suspended to be resumed as soon as reasonably practicable after delivery of a
Suspension Notice to the Investors. In addition to and without limiting any other remedies (including, without limitation, at law or at equity) available to the Investor, the Investor shall be entitled to specific performance in the event that the
Company fails to comply with the provisions of this Section 6.2(c). 
 (d) Notwithstanding the
foregoing paragraphs of this Section 6.2, the Company shall use its commercially reasonable efforts to ensure that (i) a Suspension shall not exceed thirty (30) days individually, (ii) no more than two (2) Suspensions shall
occur during any twelve month period and (iii) each Suspension shall be separated by a period of at least thirty (30) days from a prior Suspension (each Suspension that satisfies the foregoing criteria being referred to herein as a
“Qualifying Suspension”). If a Suspension occurs and such Suspension is not a Qualifying Suspension (a “Non-Qualifying Suspension”), the Company shall, on the
10th Business Day immediately following the effectiveness
of the Non-Qualifying Suspension and each 30th day
thereafter, make a payment to the Investor as partial compensation for such Non-Qualifying Suspension equal to 1.5% of the purchase price paid for the Shares that are convertible into Registrable Securities purchased by the Investor and not
previously sold by the Investor until the Non-Qualifying Suspension has ended; provided, however, that in no event shall the payments made pursuant to this paragraph (d), if any, exceed in the aggregate 5% of the purchase price paid by the Investor
for the Shares that are convertible into Registrable Securities; provided, further, that in all events such penalties under this paragraph (d) shall cease to accrue with respect to any Investor on the date on which such Investor may sell
Registrable Securities pursuant to Rule 144 without limitations on volume or manner of sales. 
 (e) If a Suspension is
not then in effect, the Investor may sell Registrable Securities under the Registration Statement, provided that it complies with any applicable prospectus delivery requirements. Upon receipt of a request therefor, the Company will provide an
adequate number of current Prospectuses to the Investor and to any other parties requiring such Prospectuses. 
 (f) In
the event of a sale of Registrable Securities by the Investor, unless such requirement is waived by the Company in writing, the Investor must also deliver to the Company’s transfer agent, with a copy to the Company, a Certificate of Subsequent
Sale substantially in the form attached hereto as Exhibit C, so that the securities may be properly transferred. 
 (g)
The Company agrees that it shall, immediately prior to the Registration Statement being declared effective, deliver to its transfer agent an opinion letter of counsel, opining that at any time the Registration Statement is effective, the
transfer agent shall issue, in connection with the sale of the Registrable Securities, certificates representing such securities without restrictive legend, provided the Registrable Securities are to be sold pursuant to the prospectus contained in
the Registration Statement and the transfer agent receives a Certificate of Subsequent Sale in the form attached hereto as Exhibit C. Upon receipt of such opinion, the Company shall cause the transfer agent to confirm, for the benefit of the
Investor, that no further opinion of counsel is required at the time of transfer in order to issue such Registrable Securities without restrictive legend. 

The Company shall cause its transfer agent to issue a certificate without any restrictive legend to a purchaser of any Securities from
the Investor, if (a) the sale of such Registrable Securities is registered under the Registration Statement (including registration pursuant to Rule 415 

 

 15 

 
under the Securities Act) and the Investor has delivered a Certificate of Subsequent Sale to the Transfer Agent; (b) the holder has provided the Company with an opinion of counsel, in form,
substance and scope customary for opinions of counsel in comparable transactions, to the effect that a public sale or transfer of such Securities may be made without registration under the Securities Act; or (c) such Securities are sold in
compliance with Rule 144 under the Securities Act. In addition, the Company shall, at the request of the Investor, remove the restrictive legend from any Shares held by the Investor following the expiration of the requirement for such restrictive
legend under Rule 144 under the Securities Act (or any successor rule). Each Investor, severally and not jointly with the other Investors, agrees that such Investor will sell any Securities pursuant to either the registration requirements of the
Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom, and that if Securities are Registrable Securities held by an Investor that are sold pursuant to the Registration Statement, they will be sold in
compliance with the plan of distribution set forth therein, and acknowledges that the removal of the restrictive legend from certificates representing Securities as set forth in this Section 6.2 is predicated upon the Company’s reliance
upon this understanding. 
 6.3 Securities Ineligible for Registration; Transfer Restrictions. 

(a) Investors hereby acknowledge and agree that the Securities are “restricted securities” under applicable U.S.
federal and state securities laws and that, pursuant to these laws, the Investor must hold the Securities (including shares of common stock issuable upon conversion or exercise thereof) indefinitely unless they are registered with the SEC and
qualified by state authorities, or an exemption from such registration and qualification requirements is available. The Investors acknowledge that the Company has no obligation to register or qualify any of the Securities (including shares of common
stock issuable upon conversion or exercise thereof) for resale, except for the registration rights in Sections 6.1 and 6.2 hereof which pertain only to the Investors and only with respect to Securities which qualify as Registrable Securities. The
Investors further acknowledge that if an exemption from registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the Securities, and
on requirements relating to the Company which are outside of the Investor’s control. 
 (b) Subject to
Section 6.2(g) above, the Investors agree to the imprinting on any of the Securities in the following form: 

THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY
STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE
SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO
THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL
INSTITUTION THAT IS AN “ACCREDITED INVESTOR” AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES. 
  

 16 

 The Company acknowledges and agrees that an Investor may from time to time pledge pursuant to a bona fide
margin agreement with a registered broker-dealer or grant a security interest in some or all of the Securities to a financial institution that is an “accredited investor” as defined in Rule 501(a) under the Securities Act and who agrees to
be bound by the provisions of this Agreement and, if required under the terms of such arrangement, such Investor may transfer pledged or secured Securities to the pledgees or secured parties. Such a pledge or transfer would not be subject to
approval of the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall be required of such pledge. At the appropriate Investors’ expense, the
Company will execute and deliver such reasonable documentation as a pledgee or secured party of Securities may reasonably request in connection with a pledge or transfer of the Securities, including, if the Securities are subject to registration
rights with the SEC, the preparation and filing of any required prospectus supplement under Rule 424(b)(3) under the Securities Act or other applicable provision of the Securities Act to appropriately amend the list of Selling Stockholders
thereunder. 
 6.4 Indemnification. For the purpose of this Section 6.4: 

(a) the term “Selling Stockholder” shall mean the Investor and each person, if any, who controls the Investor
within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act; 
 (b) the term
“Registration Statement” shall include any final Prospectus, exhibit, supplement or amendment included in or relating to, and any document incorporated by reference in, the Registration Statement (or deemed to be a part thereof)
referred to in Section 6.1; and 
 (c) the term “untrue statement” shall mean any untrue statement
or alleged untrue statement, or any omission or alleged omission to state in the Registration Statement a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they
were made, not misleading. 
 (d) (i) The Company agrees to indemnify and hold harmless each Selling Stockholder from
and against any losses, claims, damages or liabilities to which such Selling Stockholder may become subject (under the Securities Act or otherwise) insofar as such losses, claims, damages or liabilities (or actions or proceedings in respect thereof)
arise out of, or are based upon (i) any untrue statement of a material fact contained in the Registration Statement, (ii) any inaccuracy in the representations and warranties of the Company contained in the Agreement or the failure of the
Company to perform its obligations hereunder or (iii) any failure by the Company to fulfill any undertaking included in the Registration Statement, and the Company will reimburse such Selling Stockholder for any reasonable legal expense or
other actual accountable out of pocket expenses reasonably incurred in investigating, defending or preparing to defend any such action, proceeding or claim; provided, however, that the Company shall not be liable in any such case to the extent that
such loss, claim, damage or liability arises out of, or is based upon, an untrue statement made in such Registration Statement in reliance upon and in conformity with written information furnished to the Company by or on behalf of such Selling
Stockholder specifically for use in preparation of the Registration Statement, or any inaccuracy in representations made by such Selling Stockholder in the Investor Questionnaire or the failure of such Selling Stockholder to comply with its
covenants and agreements contained in Sections 4.1, 4.2, 4.3, 4.4 or 6.2 hereof or any statement or omission in any Prospectus that is corrected in any subsequent Prospectus that was delivered to the Selling Stockholder prior to the pertinent sale
or sales by the Selling Stockholder. 
 (ii) The Investor agrees to indemnify and hold harmless the Company (and each
person, if any, who controls the Company within the meaning of Section 15 of the 
  

 17 

 
Securities Act, each officer of the Company who signs the Registration Statement and each director of the Company) from and against any losses, claims, damages or liabilities to which the Company
(or any such officer, director or controlling person) may become subject (under the Securities Act or otherwise), insofar as such losses, claims, damages or liabilities (or actions or proceedings in respect thereof) arise out of, or are based upon,
(i) any failure to comply with the covenants and agreements contained in Section 4.1, 4.2, 4.3, 4.4 or 6.2 hereof, or (ii) any untrue statement of a material fact contained in the Registration Statement if, and only if, such untrue
statement was made in reliance upon and in conformity with written information furnished by or on behalf of the Investor specifically for use in preparation of the Registration Statement, and the Investor will reimburse the Company (or such officer,
director or controlling person), as the case may be, for any reasonable legal expense or other actual accountable out-of-pocket expenses reasonably incurred in investigating, defending or preparing to defend any such action, proceeding or claim. The
obligation to indemnify shall be limited to the net amount of the proceeds received by the Investor from the sale of the Shares pursuant to the Registration Statement. 

(iii) Promptly after receipt by any indemnified person of a notice of a claim or the beginning of any action in respect of which
indemnity is to be sought against an indemnifying person pursuant to this Section 6.4, such indemnified person shall notify the indemnifying person in writing of such claim or of the commencement of such action, but the omission to so notify
the indemnifying party will not relieve it from any liability which it may have to any indemnified party under this Section 6.4 (except to the extent that such omission materially and adversely affects the indemnifying party’s ability to
defend such action) or from any liability otherwise than under this Section 6.4. Subject to the provisions hereinafter stated, in case any such action shall be brought against an indemnified person, the indemnifying person shall be entitled to
participate therein, and, to the extent that it shall elect by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, shall be entitled to assume the defense thereof, with counsel
reasonably satisfactory to such indemnified person. After notice from the indemnifying person to such indemnified person of its election to assume the defense thereof (unless it has failed to assume the defense thereof and appoint counsel reasonably
satisfactory to the indemnified party), such indemnifying person shall not be liable to such indemnified person for any legal expenses subsequently incurred by such indemnified person in connection with the defense thereof; provided, however, that
if there exists or shall exist a conflict of interest that would make it inappropriate, in the reasonable opinion of counsel to the indemnified person, for the same counsel to represent both the indemnified person and such indemnifying person or any
affiliate or associate thereof, the indemnified person shall be entitled to retain its own counsel at the expense of such indemnifying person; provided, however, that no indemnifying person shall be responsible for the fees and expenses of more than
one separate counsel (together with appropriate local counsel) for all indemnified parties. In no event shall any indemnifying person be liable in respect of any amounts paid in settlement of any action unless the indemnifying person shall have
approved the terms of such settlement; provided that such consent shall not be unreasonably withheld. No indemnifying person shall, without the prior written consent of the indemnified person, effect any settlement of any pending or threatened
proceeding in respect of which any indemnified person is or could reasonably have been a party and indemnification could have been sought hereunder by such indemnified person, unless such settlement includes an unconditional release of such
indemnified person from all liability on claims that are the subject matter of such proceeding. 
 (iv) If the
indemnification provided for in this Section 6.4 is unavailable to or insufficient to hold harmless an indemnified party under subsection (d)(i) or (d)(ii) above in respect of any losses, claims, damages or liabilities (or actions or
proceedings in respect thereof) referred to therein, then each indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities (or actions in respect thereof) in
such proportion as is appropriate to reflect the relative fault of the Company on the one hand and the Investor on the other in connection with the statements or omissions or other matters which resulted in

  

 18 

 
such losses, claims, damages or liabilities (or actions in respect thereof), as well as any other relevant equitable considerations. The relative fault shall be determined by reference to, among
other things, in the case of an untrue statement, whether the untrue statement relates to information supplied by the Company on the one hand or the Investor on the other and the parties’ relative intent, knowledge, access to information and
opportunity to correct or prevent such untrue statement. The Company and the Investor agree that it would not be just and equitable if contribution pursuant to this subsection (d) were determined by pro rata allocation (even if the Investors
were treated as one entity for such purpose) or by any other method of allocation which does not take into account the equitable considerations referred to above in this subsection (d)(iv). The amount paid or payable by an indemnified party as a
result of the losses, claims, damages or liabilities (or actions in respect thereof) referred to above in this subsection (d) shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection
with investigating or defending any such action or claim. Notwithstanding the provisions of this subsection (d), the Investor shall not be required to contribute any amount in excess of the amount by which the net amount received by the Investor
from the sale of the Shares to which such loss relates exceeds the amount of any damages which the Investor has otherwise been required to pay by reason of such untrue statement. No person guilty of fraudulent misrepresentation (within the meaning
of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Investors’ obligations in this subsection to contribute are several in proportion to
their sales of Shares to which such loss relates and not joint. 
 The parties to this Agreement hereby acknowledge that they
are sophisticated business persons who were represented by counsel during the negotiations regarding the provisions hereof including, without limitation, the provisions of this Section 6.4, and are fully informed regarding said provisions. They
further acknowledge that the provisions of this Section 6.4 fairly allocate the risks in light of the ability of the parties to investigate the Company and its business in order to assure that adequate disclosure is made in the Registration
Statement as required by the Securities Act and the Exchange Act. 
 6.5 Termination of Conditions and Obligations. The
conditions precedent imposed by Section 4 or this Section 6 upon the transferability of the Securities shall cease and terminate as to any particular number of the Shares when such Shares shall have been effectively registered under the
Securities Act and sold or otherwise disposed of in accordance with the intended method of disposition set forth in the Registration Statement covering such Shares or at such time as an opinion of counsel satisfactory to the Company shall have been
rendered to the effect that such conditions are not necessary in order to comply with the Securities Act. 
 6.6 Information
Available. So long as the Registration Statement is effective covering the resale of Registrable Securities owned by the Investor, the Company will furnish (or, to the extent such information is available electronically through the
Company’s filings with the SEC, the Company will make available) to the Investor: 
 (a) as soon as practicable
after it is available, one copy of (i) its Annual Report to Stockholders (which Annual Report shall contain consolidated financial statements audited in accordance with generally accepted accounting principles by a national firm of certified
public accountants) and (ii) if not included in substance in the Annual Report to Stockholders, its Annual Report on Form 10-K (the foregoing, in each case, excluding exhibits); 

(b) upon the reasonable request of the Investor, all exhibits excluded by the parenthetical to subparagraph (a)(ii) of this
Section 6.6 as filed with the SEC and all other information that is made available to shareholders; and 
  

 19 

 (c) upon the reasonable request of the Investor, an adequate number of copies of the
Prospectuses to supply to any other party requiring such Prospectuses; and the Company, upon the reasonable request of the Investor, will meet with the Investor or a representative thereof at the Company’s headquarters during the Company’s
normal business hours to discuss all information relevant for disclosure in the Registration Statement covering the Registrable Securities and will otherwise reasonably cooperate with the Investor conducting an investigation for the purpose of
reducing or eliminating the Investor’s exposure to liability under the Securities Act, including the reasonable production of information at the Company’s headquarters; provided, that the Company shall not be required to disclose any
confidential information to or meet at its headquarters with the Investor until and unless the Investor shall have entered into a confidentiality agreement in form and substance reasonably satisfactory to the Company with the Company with respect
thereto. 
 6.7 Public Statements. By 7:30 a.m., Eastern time, on the trading day immediately following the execution of
this Agreement, the Company shall issue one or more press releases disclosing all material terms of the transactions contemplated hereby. The Company agrees to disclose on a Current Report on Form 8-K the existence of the Offering and the material
terms, thereof, including pricing, within one (1) Business Day after the Closing. Such Current Report on Form 8-K shall include a form of this Agreement as an exhibit thereto. The Company will not issue any public statement, press release or
any other public disclosure listing the Investor as one of the purchasers of the Securities without the Investor’s prior written consent, except as may be required by applicable law or rules of any exchange on which the Company’s
securities are listed. 
 7. Notices. All notices, requests, consents and other communications hereunder shall be in
writing, shall be delivered (A) if within the United States, by first-class registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, or by facsimile, or (B) if from outside the United States, by
International Federal Express (or comparable service) or facsimile, and shall be deemed given (i) if delivered by first-class registered or certified mail domestic, upon the Business Day received, (ii) if delivered by nationally recognized
overnight carrier, one (1) Business Day after timely delivery to such carrier, (iii) if delivered by International Federal Express (or comparable service), two (2) Business Days after so mailed, (iv) if delivered by facsimile,
upon electric confirmation of receipt and shall be addressed as follows, or to such other address or addresses as may have been furnished in writing by a party to another party pursuant to this paragraph: 

(a) if to the Company, to: 

EnteroMedics Inc. 

2800 Patton Road 

St. Paul, MN 55113 

			
	Attention:	 	Mark B. Knudson, Ph.D., President and CEO
	Telephone:	 	(651) 634-3033
	Facsimile:	 	(651)

 with a copy to: 

Dorsey & Whitney LLP 

Suite 1500, 50 South Sixth Street 

Minneapolis, Minnesota 55402-1498 

Attn: Kenneth L. Cutler, Esq. 

			
	Telephone:	 	(612) 340-2600
	Facsimile:	 	(612)

  

 20 

 (b) if to the Investor, at its address on the signature page to the Securities
Purchase Agreement. 
 8. Amendments; Waiver. This Agreement may not be modified or amended except pursuant to an
instrument in writing signed by the Company and the Investor. Any waiver of a provision of this Agreement must be in writing and executed by the party against whom enforcement of such waiver is sought. 

9. Headings. The headings of the various sections of this Agreement have been inserted for convenience of reference only and shall
not be deemed to be part of this Agreement. 
 10. Entire Agreement; Severability. This Agreement sets forth the entire
agreement and understanding of the parties relating to the subject matter hereof and supersedes all prior and contemporaneous agreements, negotiations and understandings between the parties, both oral and written relating to the subject matter
hereof. If any provision contained in this Agreement is determined to be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or
impaired thereby. 
 11. Governing Law. This Agreement shall be governed by, and construed in accordance with, the
internal laws of the State of Delaware, without giving effect to the principles of conflicts of law. 
 12. Expenses. If
the Closing is effected, the Company shall, at the Closing, reimburse the reasonable fees and out-of-pocket expenses of Jones Day (“Counsel”); provided, that the legal fees and expenses to be reimbursed to Counsel shall not, in the
aggregate, exceed $25,000 provided, further, that the Investors shall submit reasonably detailed invoices to the Company evidencing that such fees and expenses have been incurred. The Investors acknowledge that payment of Counsel fees
by the Company raises a potential conflict of interest and hereby consents to the payment arrangement set forth herein. 

13. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall constitute an original, but all
of which, when taken together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and delivered to the other parties. 

 

 21 

 Exhibit A 

EnteroMedics Inc. 

SECURITIES CERTIFICATE QUESTIONNAIRE 

Pursuant to Section 4 of the Agreement, please provide us with the following information: 

 

							
	1.	  	The exact name in which your Securities are to be registered (this is the name that will appear on your book entry statements. You may use a nominee name if appropriate:	  	  
	  	
				
	2.	  	The relationship between the Investor and the registered holder listed in response to item 1 above:	  	  
	  	
				
	3.	  	The mailing address, telephone and fax number and e-mail address of the registered holder listed in response to item 1 above:	  	  
	  	
				
	4.	  	The Social Security Number or Tax Identification Number of the registered holder listed in the response to item 1 above:	  	  
	  	

  

 1 

 EXHIBIT B 

EnteroMedics Inc. 

INVESTOR QUESTIONNAIRE 

(All information will be treated confidentially) 

To: EnteroMedics Inc., 
 This
Investor Questionnaire (“Questionnaire”) must be completed by each potential investor in connection with the offer and sale of the shares of the Series A Non-Voting Convertible Preferred Stock, par value $.01 per share (the
“Shares”), and warrants to purchase common stock (the “Warrants” and, together with the Shares, the “Securities”), of EnteroMedics Inc. (the “Company”). The Securities are being
offered and sold by the Company without registration under the Securities Act of 1933, as amended (the “Securities Act”), and the securities laws of certain states, in reliance on the exemptions contained in Section 4 of the
Securities Act and on Regulation D promulgated thereunder and in reliance on similar exemptions under applicable state laws. The Company must determine that a potential investor meets certain suitability requirements before offering or selling
Securities to such investor. The purpose of this Questionnaire is to assure the Company that each investor will meet the applicable suitability requirements. The information supplied by you will be used in determining whether you meet such criteria,
and reliance upon the private offering exemption from registration is based in part on the information herein supplied. 
 This
Questionnaire does not constitute an offer to sell or a solicitation of an offer to buy any security. Your answers will be kept strictly confidential. However, by signing this Questionnaire you will be authorizing the Company to provide a completed
copy of this Questionnaire to such parties as the Company deems appropriate in order to ensure that the offer and sale of the Securities will not result in a violation of the Securities Act or the securities laws of any state and that you otherwise
satisfy the suitability standards applicable to purchasers of the Shares. All potential investors must answer all applicable questions and complete, date and sign this Questionnaire. Please print or type your responses and attach additional sheets
of paper if necessary to complete your answers to any item. 
  

	A.	BACKGROUND INFORMATION 

  

			
	 Name:
	 	  

 

			
	 Business Address:
	 	  

					
		 	(Number and Street)	 	
	
	  

	 (City)
	 	(State)	 	(Zip Code)

  

			
	 Telephone Number: (            )
	  	  

 

			
	Residence Address:	  	  

					
		 	(Number and Street)	 	
	
	  

	 (City)
	 	(State)	 	(Zip Code)

  

			
	 Telephone Number: (            )
	  	  

 

			
	Residence Address:	  	  

					
		 	(Number and Street)	 	
	
	  

	 (City)
	 	(State)	 	(Zip Code)

  

					
			
	 If an individual:
	  		  	

					
	Age:             	  	Citizenship:                 	  	Where registered to vote:                   
         
	
	If a corporation, partnership, limited liability company, trust or other entity:

					
		
	Type of entity:	  	  

 

			
		
	State of formation:                      	  	Date of
formation:                                        
                    

  

 1 

			
	Social Security or Taxpayer Identification No.	  	  

 

			
	 Send all correspondence to (check one):              Residence
Address
	  	             Business Address

 

	B.	STATUS AS ACCREDITED INVESTOR 

The undersigned is an “accredited investor” as such term is defined in Regulation D under the Securities Act, because at the time of the sale of
the Securities the undersigned falls within one or more of the following categories (Please initial one or more, as applicable): 

INDIVIDUALS 
  

			
	             A.	  	The undersigned is a natural person whose individual net worth, or joint net worth with his or her spouse, excluding the value of his or her primary residence net of any mortgage
obligation secured by the property, exceeds $1 million.
		
	             B.	  	The undersigned is an individual (not a partnership, corporation, etc.) with income in excess of $200,000 in each of the prior two years and reasonably expects an income in
excess of $200,000 in the current year.
		
	             C.	  	The undersigned is an individual (not a partnership, corporation, etc.) who, with his or her spouse, had joint income in excess of $300,000 in each of the prior two years and
reasonably expects joint income in excess of $300,000 in the current year.
		
	             D.	  	The undersigned is a director or executive officer of the Company.

ENTITIES 
  

			
	             E.	  	The undersigned, if other than an individual, is an entity all of whose equity owners meet one of the tests set forth in (a) through (d) above.
		
	              F.
	  	The undersigned is an entity, and is an “Accredited Investor” as defined in Rule 501(a) of Regulation D under the Act. This representation is based on the following
(check one or more, as applicable):

  

			
	             1.	  	The undersigned (or, in the case of a trust, the undersigned trustee) is a bank or savings and loan association as defined in Sections 3(a)(2) and 3(a)(5)(A), respectively, of
the Act acting either in its individual or fiduciary capacity; or a broker or dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934.
		
	             2.	  	The undersigned is an insurance company as defined in Section 2(13) of the Act.
		
	             3.	  	The undersigned is an investment company registered under the Investment Company Act of 1940 or a business development company as defined in Section 2(a)(48) of that
Act.
		
	             4.	  	The undersigned is a Small Business Investment Company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of
1958.
		
	             5.	  	The undersigned is an employee benefit plan within the meaning of Title I of the Employee Retirement Income Security Act of 1974 (“ERISA”) and either (check all that
apply):

  

			
	             a.	  	the investment decision is made by a plan fiduciary, as defined in Section 3(21) of ERISA, which is either a bank, savings and loan association, insurance company, or registered
investment adviser; or

  

 B-2 

			
	             b.	  	the employee benefit plan has total assets in excess of $5,000,000; or
		
	             c.	  	the plan is a self-directed plan with investment decisions made solely by or for the account of persons who are “Accredited Investors” as defined under the
Act.

  

			
	             6.	  	The undersigned is a private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940.
		
	             7.	  	The undersigned has total assets in excess of $5,000,000, was not formed for the specific purpose of acquiring securities of the Company and is one or more of the following
(check one or more, as appropriate):

  

			
	             a.	  	an organization described in Section 501(c)(3) of the Internal Revenue Code; or
		
	             b.	  	a corporation; or
		
	             c.	  	a Massachusetts or similar business trust; or
		
	             d.	  	a partnership.

  

			
	             8.	  	The undersigned is a trust with total assets exceeding $5,000,000 which was not formed for the specific purpose of acquiring securities of the Company and whose purchase is
directed by a person who has such knowledge and experience in financial and business matters that he is capable of evaluating the merits and risks of the investment in the Securities.
		
	             9.	  	The undersigned is a plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions for the
benefit of its employees, if such plan has total assets in excess of $5,000,000

 C. REPRESENTATIONS

 The undersigned hereby represents and warrants to the Company as follows: 

1. Any purchase of the Securities would be solely for the account of the undersigned and not for the account of any other person
or with a view to any resale, fractionalization, division, or distribution thereof. 
 2. The information contained
herein is complete and accurate and may be relied upon by the Company, and the undersigned will notify the Company immediately of any material change in any of such information occurring prior to the closing, if any, with respect to the purchase of
Securities by the undersigned or any co-purchaser. 
 3. There are no suits, pending litigation, or claims against the
undersigned that could materially affect the net worth of the undersigned as reported in this Questionnaire. 
 4. The
undersigned acknowledges that the number of Securities that may be registered for resale under the Securities Act with the Securities and Exchange Commission may be limited as described in Section 6.1 of the Agreement. The undersigned
acknowledges that, with respect to Registrable Securities held by Investors, there may occasionally be times when the Company, based on the advice of its counsel, determines that it must suspend the use of the Prospectus forming a part of the
Registration Statement (as such terms are defined in the Securities Purchase Agreement to which this Questionnaire is attached) until such time as an amendment to the Registration Statement has been filed by the Company and declared effective by the
Securities and Exchange Commission or until the Company has amended or supplemented such Prospectus. The undersigned is aware that, in such event, any Securities that constitute Registrable Securities will not be subject to ready liquidation, and
that any Registrable Securities purchased by the undersigned would have to be held during such suspension. The overall commitment of 

 

 B-3 

 
the undersigned to investments which are not readily marketable is not excessive in view of the undersigned’s net worth and financial circumstances, and any purchase of the Securities will
not cause such commitment to become excessive. The undersigned is able to bear the economic risk of an investment in the Securities. 

5. The undersigned has carefully considered the potential risks relating to the Company and a purchase of the Securities and fully
understands that the Securities are speculative investments which involve a high degree of risk of loss of the undersigned’s entire investment. Among others, the undersigned has carefully considered each of the risks described in the
Company’s Annual Report on Form 10-K for the year ended December 31, 2009. 
 6. The following is a list of all
states and other jurisdictions in which blue sky or similar clearance will be required in connection with the undersigned’s purchase of the Securities: 
  

	
	  

	  

	  

The undersigned agrees to notify the Company in writing of any additional states or other jurisdictions in which blue sky or similar clearance will be
required in connection with the undersigned’s purchase of the Securities. 
  

 B-4 

 IN WITNESS WHEREOF, the undersigned has executed this Questionnaire this
             day of                         , 2010, and
declares under oath that it is truthful and correct. 
  

			
	Print Name
		
	 By:
	 	  

	 Signature

		
	 Title:
	 	  

		 	(required for any purchaser that is a corporation, partnership, trust or other entity)

 

 B-5 

 EXHIBIT C 

ENTEROMEDICS INC. 

CERTIFICATE OF SUBSEQUENT SALE 
  

			
	[Transfer Agent]	 	
	  
	 	
	  
	 	

  

	 	RE:	Sale of Shares of Common Stock of EnteroMedics Inc. (the “Company”) pursuant to the Company’s Prospectus dated
                    , 2010 (the “Prospectus”) 

Dear Sir/Madam: 
 The
undersigned hereby certifies, in connection with the sale of shares of Common Stock of the Company included in the table of Selling Shareholders in the Prospectus, that the undersigned has sold the Shares pursuant to the Prospectus and in a manner
described under the caption “Plan of Distribution” in the Prospectus and that such sale complies with all applicable securities laws, including, without limitation, the Prospectus delivery requirements of the Securities Act of 1933, as
amended. 
  

			
	Selling Stockholder (the beneficial owner):	 	  

 

			
	Record Holder (e.g., if held in name of nominee):	 	  

 

			
	Restricted Stock Certificate No.(s):	 	  

 

			
	Number of Shares Sold:	 	  

 

			
	Date of Sale:	 	  

In the event that you receive a stock certificate(s) representing more shares of Common Stock than have been sold by the undersigned,
then you should return to the undersigned a newly issued certificate for such excess shares in the name of the Record Holder and BEARING A RESTRICTIVE LEGEND. Further, you should place a stop transfer on your records with regard to such certificate.

  

											
	Dated:	 		 		 	Very truly yours,
					
		 		 		 	By:	 	  

					
		 		 		 	Print Name:	 	  

					
		 		 		 	Title:	 	  

 

 1 

 EXHIBIT D 

FORM OF LEGAL OPINION 

September 29, 2010 
  

	To:	The Purchasers of Series A Non-Voting Convertible Preferred Stock of EnteroMedics Inc. 

Ladies and Gentlemen: 

Reference is hereby made to the several Securities Purchase Agreements, dated as of the date hereof (the “Agreement”), by and
among EnteroMedics Inc., a Delaware corporation (the “Company”), and each person identified as an Investor therein (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used herein shall have the
meanings assigned to them in the Agreement. 
 We have acted as counsel to the Company in connection with the issuance under the
Agreement of up to 3,394,309 shares of the Company’s Series A Non-Voting Convertible Preferred Stock, $0.01 par value per share, Up Front Warrants to purchase up to 3,394,309 shares of the Company’s Common Stock, $0.01 par value per share
and the Conversion Warrants. This opinion is being delivered to you pursuant to Section 2 of the Agreement. 
 We have
examined such documents and have reviewed such questions of law as we have considered necessary or appropriate for the purpose of this opinion. 

In rendering our opinions, we have assumed the authenticity of all documents submitted to us as originals, the genuineness of all
signatures and the conformity to authentic originals of all documents submitted to us as copies. We have also assumed the legal capacity for all purposes relevant hereto of all natural persons and, with respect to all parties to agreements or
instruments relevant hereto other than the Company, that such parties had the requisite power and authority (corporate or otherwise) to execute, deliver and perform such agreements or instruments, that such agreements or instruments have been duly
authorized by all requisite action (corporate or otherwise) on behalf of such parties, executed and delivered by such parties and that such agreements or instruments are the valid, binding and enforceable obligations of such parties. As to questions
of fact material to our opinions, we have relied upon certificates of officers of the Company, including certificates being delivered to you at the Closing. 

Our opinions expressed below as to certain factual matters are qualified as being limited “to our knowledge” or by other words
to the same or similar effect. Such words, as used herein, mean the information known to Kenneth L. Cutler, Timothy S. Hearn, Michael W. Clausman and Jenna L. Hannigan, the attorneys in this firm who have represented the Company in connection with
the matters addressed herein. In rendering such opinions, we have not consulted with other attorneys in our firm with respect to the matters covered thereby, 

 

 1 

 
and we have conducted no review of documents in our files relating to any other matters in which this firm has represented the Company. No inference as to our knowledge with respect to such
matters should be drawn from the fact of our representation of the Company. 
 On the basis of the foregoing and of our
examination of such other questions of law and fact as we deem relevant under the circumstances, and in reliance thereon, and subject to the limitations, qualifications, presumptions and exceptions set forth herein, we are of the opinion that:

 Based on the foregoing, we are of the opinion that: 

1. The Company is a corporation duly incorporated, validly existing and in good standing under the laws of the State of Delaware, with the
corporate power to conduct any lawful business activity. The Company has the corporate power to execute, deliver and perform the Agreement including, without limitation, the issuance and sale of the Shares, the Warrants and, upon due exercise by the
Investors of the Warrants, the issuance and sale of the Warrant Shares. 
 2. The Transaction Documents have been duly
authorized by all requisite corporate action, executed and delivered by the Company. The Transaction Documents constitute the valid and binding agreement of the Company enforceable in accordance with their terms. 

3. As of the date hereof, the authorized capital stock of the Company consists of 85,000,000 shares of common stock, par value $0.01 per
share, and 5,000,000 shares of preferred stock, par value $0.01 per share, of which 3,600,000 shares have been designated as Series A Non-Voting Convertible Preferred Stock. 

4. The execution, delivery and performance of the Transaction Documents and the issuance and sale of the Securities in accordance with
the Agreement will not: (a) violate or conflict with, or result in a breach of or default under, the Certificate of Incorporation or by-laws of the Company, (b) violate or conflict with, or constitute a default under any material agreement
or instrument (limited, with your consent, to agreements filed with the Securities and Exchange Commission under the Exchange Act and applicable rules and regulations) to which the Company is a party, or (c) violate any law of the United States
or the State of Delaware, any rule or regulation of any governmental authority or regulatory body of the United States or the State of Delaware or any judgment, order or decree known to us and applicable to the Company of any court, governmental
authority or arbitrator. 
 5. To our knowledge, no consent, approval, authorization or order of, and no notice to or filing
with, any governmental agency or body or any court is required to be obtained or made by the Company for the issue and sale of the Securities pursuant to the Agreement, except such as have been obtained or made and such as may be required under the
federal securities laws or the Blue Sky laws of the various states. 
 6. Assuming the representations made by the Investors and
the Company set forth in the Agreement are true and correct, the offer, sale, issuance and delivery of the Securities to the Investors, in the manner contemplated by the Agreement, does not need to be registered under the Securities Act, it being
understood that no opinion is expressed as to any subsequent resale of such shares. 
  

 2 

 7. We know of no pending or overtly threatened lawsuit or claim against the Company which is
required to be described in the reports filed or required to be filed by the Company with the Securities and Exchange Commission under the Exchange Act. 

8. The issuance of the Securities, in accordance with the Agreement, does not require approval of the Company’s stockholders
pursuant to Nasdaq Marketplace Rule 5635(d). 
 The opinions set forth above are subject to the following qualifications and
exceptions: 
 (a) Our opinions in paragraph 2 above are subject to the effect of (i) any applicable bankruptcy,
insolvency, reorganization, moratorium, arrangement, fraudulent transfer or other similar law affecting creditors’ rights generally and (ii) principles of equity, including (without limitation) concepts of materiality, reasonableness, good
faith and fair dealing, election of remedies, estoppel and other similar doctrines affecting the enforceability of agreements generally (regardless of whether considered in a proceeding in equity or at law). 

(b) Our opinions in paragraph 2 above, insofar as they relate to indemnification provisions, are subject to the effect of federal and
state securities laws and public policy relating thereto. 
 (c) We express no opinion as to the compliance or the effect of
noncompliance by the Investors with any state or federal laws or regulations applicable to the Investors in connection with the transactions described in the Agreement. 

Our opinions expressed above are limited to the laws of the State of Minnesota, the Delaware General Corporation Law and the federal
laws of the United States of America. 
 We express no opinion regarding the accuracy of any financial representations in the
Agreement or the financial status of the Company. 
 The foregoing opinion is given solely for your benefit, speaks only as of
the date hereof, may not be relied upon by any other person or entity and shall not be copied or distributed to any other person or entity without our prior express written consent. We specifically disclaim any obligation to inform you of any change
in law, facts or circumstances which may be brought to our attention subsequent to the date hereof. 
 Very truly yours,

 KLC 
  

 3 

 EXHIBIT E 

FORMS OF WARRANTS 

(See attached) 
  

 4 

 EXHIBIT E-1 

FORM OF UP FRONT WARRANT 

(See attached) 

EXHIBIT E-2 
 FORM OF
CONVERSION WARRANT 
 (See attached) 
  

 5 

 Exhibit F 

SELLING SECURITYHOLDER NOTICE AND QUESTIONNAIRE

 The undersigned beneficial owner of common stock (the “Registrable Securities”) of EnteroMedics Inc., a
Delaware corporation (the “Company”), understands that the Company has filed or intends to file with the Securities and Exchange Commission (the “Commission”) a registration statement (the “Registration
Statement”) for the registration and resale under Rule 415 of the Securities Act of 1933, as amended (the “Securities Act”), of the Registrable Securities, in accordance with the terms of the Securities Purchase Agreement
(the “Securities Purchase Agreement”) to which this document is annexed. A copy of the Securities Purchase Agreement is available from the Company upon request at the address set forth below. All capitalized terms not otherwise
defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement. 
 Certain legal consequences
arise from being named as a selling securityholder in the Registration Statement and the related prospectus. Accordingly, holders and beneficial owners of Registrable Securities are advised to consult their own securities law counsel regarding the
consequences of being named or not being named as a selling securityholder in the Registration Statement and the related prospectus. 

NOTICE 

The undersigned beneficial owner (the “Selling Securityholder”) of Registrable Securities hereby elects to include the
Registrable Securities owned by it in the Registration Statement. 
  

 6 

 The undersigned hereby provides the following information to the Company and represents and warrants that
such information is accurate: 
 QUESTIONNAIRE 

1. Name. 
  

	 	(a)	Full Legal Name of Selling Securityholder 

  

 
  

	 	(b)	Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities are held: 

 
  

 

	 	(c)	Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or with others has power to vote or dispose of the securities
covered by the questionnaire): 

  
  

2. Address for Notices to Selling Securityholder: 
  

	
	  

	  

	  

			
	  Telephone:	 	  

			
	  Fax:	 	  

			
	  Contact Person:	 	  

3. Broker-Dealer Status: 
  

	 	(a)	Are you a broker-dealer? 

Yes   ̈            
No   ̈ 
  

	 	(b)	If “yes” to Section 3(a), did you receive your Registrable Securities as compensation for investment banking services to the Company.

 Yes
   ̈            No   ̈ 

 

	 	Note:	If no, the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement. 

 

 7 

	 	(c)	Are you an affiliate of a broker-dealer? 

Yes
   ̈            No   ̈ 

 

	 	(d)	If you are an affiliate of a broker-dealer, do you certify that you bought the Registrable Securities in the ordinary course of business, and at the time of the
purchase of the Registrable Securities to be resold, you had no agreements or understandings, directly or indirectly, with any person to distribute the Registrable Securities? 

Yes
   ̈            No   ̈ 

Note: If no, the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement.

 4. Beneficial Ownership of Securities of the Company Owned by the Selling Securityholder. 

Except as set forth below in this Item 4, the undersigned is not the beneficial or registered owner of any securities of the
Company other than the securities issuable pursuant to the Purchase Agreement. 
  

	 	(a)	Type and Amount of other securities beneficially owned by the Selling Securityholder: 

 

 8 

 5. Relationships with the Company: 

Except as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners
of 5% of more of the equity securities of the undersigned) has held any position or office or has had any other material relationship with the Company (or its predecessors or affiliates) during the past three years. 

State any exceptions here: 
  

 
  

 
 The undersigned
agrees to promptly notify the Company of any inaccuracies or changes in the information provided herein that may occur subsequent to the date hereof at any time while the Registration Statement remains effective. 

By signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through 5 and
the inclusion of such information in the Registration Statement and the related prospectus and any amendments or supplements thereto. The undersigned understands that such information will be relied upon by the Company in connection with the
preparation or amendment of the Registration Statement and the related prospectus. 
 IN WITNESS WHEREOF the undersigned, by
authority duly given, has caused this Notice and Questionnaire to be executed and delivered either in person or by its duly authorized agent. 
  

													
	Dated:	 	  
	 		 	Beneficial Owner:	 	  

					
		 		 		 	By:	 	  

		 		 		 		 	Name:	 		 	
		 		 		 		 	Title:	 		 	

 PLEASE FAX A COPY OF THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE, AND RETURN THE ORIGINAL BY OVERNIGHT
MAIL, TO: 
  

 9 

 EXHIBIT G 

CERTIFICATE OF DESIGNATIONS 

(See attached) 
  

 10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00179-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00179-of-00352.parquet"}]]